Paladin Labs Inc. (PLB)

Paladin Labs Inc., researches, develops, acquires, in-licenses, markets, and distributes pharmaceutical products. It focuses on various therapeutic fields, such as urology, pain and central nervous system, women’s health, allergy, endocrinology, and dermatology. The company primarily offers Abstral for the management of breakthrough pain in patients with cancer; GlucaGen for emergency treatment of hypoglycemia in insulin-dependent diabetics; Oralair for the treatment of the symptoms of seasonal grass pollen allergic rhinitis; and Metadol for use as an analgesic in acute cancer pain, palliative care, and chronic pain disorders, as well as for the detoxification or maintenance treatment of opioid-dependent individuals. Its principal products also include Plan B (Levonorgestrel), an emergency contraceptive; Pollinex-R for the pre-seasonal immunotherapy of adults and children; Seasonale, an oral contraceptive; Silenor for the treatment and symptomatic relief of insomnia; Testim for testosterone replacement therapy in adult males; Twinject, a pre-filled auto-injector for emergency treatment of severe allergic reactions; and Tridural for moderate to moderately severe pain. In addition, the company researches and develops pharmaceuticals and medical devices as well as supplies vaccines to South Africa and countries comprising the South African Development Community region. Paladin Labs Inc. was formerly known as Geriatrx Pharmaceutical Corp. and changed its name to Paladin Labs Inc. in June 1995. The company was founded in 1983 and is headquartered in St-Laurent, Canada. As of February 28, 2014, Paladin Labs Inc. operates as a subsidiary of Paladin Labs Canadian Holding Inc. On August 16, 2022, Paladin Labs Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. It is in joint administration with Endo International plc.